Table 7. Risk of ⩾CIN 2 associated with oestrogen levels in women in the luteal phase.
|
Random controls |
HPV-positive controls |
|||||||
|---|---|---|---|---|---|---|---|---|
| Cases | Ctrls | ORa | 95% CI | Cases | Ctrls | ORb | 95% CI | |
| Oestradiol | ||||||||
| ⩽71.5 pg ml−1 | 6 | 10 | 1.0 | 6 | 8 | 1.0 | ||
| 71.6–133.0 | 15 | 27 | 1.0 | (0.3–3.8) | 15 | 30 | 1.0 | (0.2–4.4) |
| ⩾133.1 | 10 | 24 | 0.5 | (0.1–2.0) | 10 | 22 | 0.8 | (0.2–3.8) |
| P-trend | 0.24 | 0.72 | ||||||
| Free oestradiol | ||||||||
| ⩽1.41 | 8 | 9 | 1.0 | 8 | 9 | 1.0 | ||
| 1.42–2.50 | 12 | 25 | 0.5 | (0.1–1.7) | 12 | 31 | 0.4 | (0.1–1.7) |
| ⩾2.51 | 11 | 24 | 0.4 | (0.1–1.4) | 11 | 15 | 1.2 | (0.3–5.0) |
| P-trend | 0.18 | 0.60 | ||||||
| Oestrone | ||||||||
| ⩽62.0 pg ml−1 | 7 | 12 | 1.0 | 7 | 9 | 1.0 | ||
| 62.1–90.0 | 9 | 19 | 0.7 | (0.2–3.0) | 9 | 18 | 0.9 | (0.2–4.1) |
| ⩾90.1 | 11 | 21 | 0.7 | (0.2–2.8) | 11 | 27 | 0.6 | (0.1–2.5) |
| P-trend | 0.68 | 0.40 | ||||||
| Oestrone sulphate | ||||||||
| ⩽1254 pg ml−1 | 6 | 11 | 1.0 | 6 | 10 | 1.0 | ||
| 1255–2287 | 14 | 21 | 1.4 | (0.4–5.3) | 14 | 19 | 1.4 | (0.3–6.1) |
| ⩾2288 | 9 | 26 | 0.7 | (0.2–2.6) | 9 | 29 | 0.6 | (0.1–2.8) |
| P-trend | 0.46 | 0.27 | ||||||
a
Adjusted for age (18–25, 26–30, 31–35, 36–40, 41+ years), days since last menstrual period (continuous), tubal ligation (never, <7 years ago, 7+ years ago) and number of lifetime sexual partners (1, 2–3, 4+).
b
Adjusted for age (18–25, 26–30, 31–35, 36–40, 41+ years), days since last menstrual period (continuous) and smoking (never, ever).